Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure.

Johannsson G, Mårin P, Lönn L, Ottosson M, Stenlöf K, Björntorp P, Sjöström L, Bengtsson BA

The Journal of clinical endocrinology and metabolism1 Mar 1997Cited by 224 (Europe PMC)

PMID9062473DOI10.1210/jcem.82.3.3809PepBankPUB-09062473

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

01HumanRandomized controlled trialEfficacy outcome
In abdominally obese men, rhGH increased glucose disposal rate compared with placebo after an initial decrease (P < 0.05).
In plain wordsIn abdominally obese men, rhGH increased glucose disposal compared with placebo after an initial decrease.
Peptide
HGH (somatotropin)
Outcome
IncreaseLater glucose disposal rate
Study
n = 30
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
9.5 micrograms/kg daily · 9 monthsAs given in this study (human).
Source sentences
Summary
After an initial decrease in the GDR at 6 weeks, the GDR increased in the rhGH-treated group as compared with the placebo-treated one (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty men, 48-66 yr old, with abdominal/visceral obesity were treated with recombinant human GH (rhGH) in a 9-month randomized, double-blind, placebo-controlled trial.
Summary · context
The daily dose of rhGH was 9.5 micrograms/kg.
Report a problemFND-0906247305
02HumanNon-randomized trialEfficacy outcome
In abdominally obese men, rhGH reduced total body fat by 9.2 +/- 2.4%.
In plain wordsIn abdominally obese men, rhGH reduced total body fat by 9.2 +/- 2.4%.
Peptide
HGH (somatotropin)
Outcome
DecreaseTotal body fat
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
9.5 micrograms/kg daily · 9 monthsAs given in this study (human).
Measurements
Total body fat decrease
9.2%
rhGH, abdominally obese men
Total body fat decrease, +/- value as reported
2.4%
rhGH, abdominally obese men
Source sentences
Summary
In response to the rhGH treatment, total body fat and abdominal sc and visceral adipose tissue decreased by 9.2 +/- 2.4%, 6.1 +/- 3.2%, and 18.1 +/- 7.6%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty men, 48-66 yr old, with abdominal/visceral obesity were treated with recombinant human GH (rhGH) in a 9-month randomized, double-blind, placebo-controlled trial.
Summary · context
The daily dose of rhGH was 9.5 micrograms/kg.
Report a problemFND-0906247301
03HumanNon-randomized trialEfficacy outcome
In abdominally obese men, rhGH reduced abdominal subcutaneous fat by 6.1 +/- 3.2%.
In plain wordsIn abdominally obese men, rhGH reduced fat beneath the abdominal skin by 6.1 +/- 3.2%.
Peptide
HGH (somatotropin)
Outcome
DecreaseAbdominal subcutaneous fat
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
9.5 micrograms/kg daily · 9 monthsAs given in this study (human).
Measurements
Abdominal subcutaneous adipose tissue decrease
6.1%
rhGH, abdominally obese men
Abdominal subcutaneous adipose tissue decrease, +/- value as reported
3.2%
rhGH, abdominally obese men
Source sentences
Summary
In response to the rhGH treatment, total body fat and abdominal sc and visceral adipose tissue decreased by 9.2 +/- 2.4%, 6.1 +/- 3.2%, and 18.1 +/- 7.6%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty men, 48-66 yr old, with abdominal/visceral obesity were treated with recombinant human GH (rhGH) in a 9-month randomized, double-blind, placebo-controlled trial.
Summary · context
The daily dose of rhGH was 9.5 micrograms/kg.
Report a problemFND-0906247302
04HumanNon-randomized trialEfficacy outcome
In abdominally obese men, rhGH reduced visceral fat by 18.1 +/- 7.6%.
In plain wordsIn abdominally obese men, rhGH reduced visceral fat by 18.1 +/- 7.6%.
Peptide
HGH (somatotropin)
Outcome
DecreaseVisceral fat
Study
n: not reported in source
Outcome group
Body composition · Metabolic and weight
Studied dose
9.5 micrograms/kg daily · 9 monthsAs given in this study (human).
Measurements
Visceral adipose tissue decrease
18.1%
rhGH, abdominally obese men
Visceral adipose tissue decrease, +/- value as reported
7.6%
rhGH, abdominally obese men
Source sentences
Summary
In response to the rhGH treatment, total body fat and abdominal sc and visceral adipose tissue decreased by 9.2 +/- 2.4%, 6.1 +/- 3.2%, and 18.1 +/- 7.6%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty men, 48-66 yr old, with abdominal/visceral obesity were treated with recombinant human GH (rhGH) in a 9-month randomized, double-blind, placebo-controlled trial.
Summary · context
The daily dose of rhGH was 9.5 micrograms/kg.
Report a problemFND-0906247303
05HumanNon-randomized trialEfficacy outcome
In abdominally obese men, rhGH decreased serum total cholesterol (P < 0.01).
In plain wordsIn abdominally obese men, rhGH decreased blood total cholesterol.
Peptide
HGH (somatotropin)
Outcome
DecreaseTotal cholesterol
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
9.5 micrograms/kg daily · 9 monthsAs given in this study (human).
Source sentences
Summary
The mean serum concentrations of total cholesterol (P < 0.01) and triglyceride (P < 0.05) decreased, whereas blood glucose and serum insulin concentrations were unaffected by the rhGH treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty men, 48-66 yr old, with abdominal/visceral obesity were treated with recombinant human GH (rhGH) in a 9-month randomized, double-blind, placebo-controlled trial.
Summary · context
The daily dose of rhGH was 9.5 micrograms/kg.
Report a problemFND-0906247306
06HumanNon-randomized trialEfficacy outcome
In abdominally obese men, rhGH decreased serum triglycerides (P < 0.05).
In plain wordsIn abdominally obese men, rhGH decreased blood triglycerides.
Peptide
HGH (somatotropin)
Outcome
DecreaseTriglycerides
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
9.5 micrograms/kg daily · 9 monthsAs given in this study (human).
Source sentences
Summary
The mean serum concentrations of total cholesterol (P < 0.01) and triglyceride (P < 0.05) decreased, whereas blood glucose and serum insulin concentrations were unaffected by the rhGH treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty men, 48-66 yr old, with abdominal/visceral obesity were treated with recombinant human GH (rhGH) in a 9-month randomized, double-blind, placebo-controlled trial.
Summary · context
The daily dose of rhGH was 9.5 micrograms/kg.
Report a problemFND-0906247307
07HumanNon-randomized trialEfficacy outcome
In abdominally obese men, blood glucose was unaffected by rhGH treatment.
In plain wordsIn abdominally obese men, rhGH did not change blood glucose.
Peptide
HGH (somatotropin)
Outcome
No significant changeBlood glucose
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
9.5 micrograms/kg daily · 9 monthsAs given in this study (human).
Source sentences
Summary
The mean serum concentrations of total cholesterol (P < 0.01) and triglyceride (P < 0.05) decreased, whereas blood glucose and serum insulin concentrations were unaffected by the rhGH treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty men, 48-66 yr old, with abdominal/visceral obesity were treated with recombinant human GH (rhGH) in a 9-month randomized, double-blind, placebo-controlled trial.
Summary · context
The daily dose of rhGH was 9.5 micrograms/kg.
Report a problemFND-0906247308
08HumanNon-randomized trialEfficacy outcome
In abdominally obese men, serum insulin was unaffected by rhGH treatment.
In plain wordsIn abdominally obese men, rhGH did not change blood insulin.
Peptide
HGH (somatotropin)
Outcome
No significant changeSerum insulin
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
9.5 micrograms/kg daily · 9 monthsAs given in this study (human).
Source sentences
Summary
The mean serum concentrations of total cholesterol (P < 0.01) and triglyceride (P < 0.05) decreased, whereas blood glucose and serum insulin concentrations were unaffected by the rhGH treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty men, 48-66 yr old, with abdominal/visceral obesity were treated with recombinant human GH (rhGH) in a 9-month randomized, double-blind, placebo-controlled trial.
Summary · context
The daily dose of rhGH was 9.5 micrograms/kg.
Report a problemFND-0906247309
09HumanNon-randomized trialEfficacy outcome
In abdominally obese men, rhGH decreased diastolic blood pressure.
In plain wordsIn abdominally obese men, rhGH decreased diastolic blood pressure.
Peptide
HGH (somatotropin)
Outcome
DecreaseDiastolic blood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
9.5 micrograms/kg daily · 9 monthsAs given in this study (human).
Source sentences
Summary
Furthermore, diastolic blood pressure decreased and systolic blood pressure was unchanged in response to rhGH treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty men, 48-66 yr old, with abdominal/visceral obesity were treated with recombinant human GH (rhGH) in a 9-month randomized, double-blind, placebo-controlled trial.
Summary · context
The daily dose of rhGH was 9.5 micrograms/kg.
Report a problemFND-0906247310
10HumanNon-randomized trialEfficacy outcome
In abdominally obese men, systolic blood pressure was unchanged with rhGH treatment.
In plain wordsIn abdominally obese men, systolic blood pressure did not change with rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeSystolic blood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Studied dose
9.5 micrograms/kg daily · 9 monthsAs given in this study (human).
Source sentences
Summary
Furthermore, diastolic blood pressure decreased and systolic blood pressure was unchanged in response to rhGH treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Thirty men, 48-66 yr old, with abdominal/visceral obesity were treated with recombinant human GH (rhGH) in a 9-month randomized, double-blind, placebo-controlled trial.
Summary · context
The daily dose of rhGH was 9.5 micrograms/kg.
Report a problemFND-0906247311

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.